TTF - Novocure surges 81% premarket after DMC recommends shorter phase 3 NSCLC trial

Novocure (NVCR) shares are up more than 81% in premarket trading after a data monitoring committee (DMC) recommended a reduced trial duration and patient numbers in its phase 3 trial for its Tumor Trial Fields (TTF) treatment for non-small cell lung cancer.The DMC told Novocure that an interim analysis of 210 patients would be accelerated.The committee also said it might be unethical for patients in the control arm to continue to 18 months of follow-up and recommended a reduced sample size of 276 patients with 12 months of follow-up.The primary endpoint of the phase 3 trial is superior overall survival when patients are treated with TTF plus immune checkpoint inhibitors or docetaxel vs immune checkpoint inhibitors or docetaxel alone.According to the company, Tumor Treating Fields is a type of cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, slowing tumor growth and potentially leading to cancer cell

For further details see:

Novocure surges 81% premarket after DMC recommends shorter phase 3 NSCLC trial